NewsBenzinga에이타이 파마, 제한성 폐질환을 동반한 만성 증상성 폐육아종증 환자 대상 주력 치료제 후보 에프조피티모드의 3상 시험 프로토콜에 대해 FDA와 합의···2026년 4분기 시험 관련 활동 개시 예정 에이타이 파마, 제한성 폐질환을 동반한 만성 증상성 폐육아종증 환자 대상 주력 치료제 후보 에프조피티모드의 3상 시험 프로토콜에 대해 FDA와 합의···2026년 4분기 시험 관련 활동 개시 예정 Benzinga 2026.09.24 10:07 (GMT+0) Open on Benzinga Other news 'China Taps US AI Models To Train Homegrown Rivals As Chip Curbs Bite' - Reuters Exclusive 'US Presses UN Agency Over Taiwan Flight Restrictions, China Hits Back' - Reuters Exclusive 'Ruined The System'? Pete Buttigieg Pushes Back On Trump's FAA Blame, Demands Accounting for Billions In Modernization Funds After 'Worst FAA Communications Breakdown This Century' Reported Earlier, NextNRG Q3 EPS $(6.88) Misses $(6.00) Estimate, Sales $26.715M Miss $28.087M Estimate Reported Earlier, Lecanemab Five-Year Clarity AD Data: 36% Lower Relative Risk Of Disease-Stage Progression Vs. ADNI, 62% Of Low-Tau Patients Improved On CDR-SB, Consistent Safety Profile, Per Eisai And Biogen Aytu BioPharma Stock Climbs 44% After-Hours: Here's Why
'Ruined The System'? Pete Buttigieg Pushes Back On Trump's FAA Blame, Demands Accounting for Billions In Modernization Funds After 'Worst FAA Communications Breakdown This Century'
Reported Earlier, NextNRG Q3 EPS $(6.88) Misses $(6.00) Estimate, Sales $26.715M Miss $28.087M Estimate
Reported Earlier, Lecanemab Five-Year Clarity AD Data: 36% Lower Relative Risk Of Disease-Stage Progression Vs. ADNI, 62% Of Low-Tau Patients Improved On CDR-SB, Consistent Safety Profile, Per Eisai And Biogen